PharmaGiant.com to Offer Generic Semaglutide

The term "generic semaglutide" is often used to describe compounded versions of the drug, which are not FDA-approved generics. Because the primary U.S. patents for brand-name semaglutide drugs like Ozempic and Wegovy do not expire until at least December 2031, there are currently no true, FDA-approved generic versions available in the United States. Compounded drugs are custom-made by pharmacies and are not subject to the same rigorous FDA testing for safety, quality, and effectiveness as commercially available medications. The FDA has issued warnings about the risks associated with these unapproved drugs, citing concerns about incorrect dosages, contamination, and the use of different active ingredients, such as semaglutide salts, which have not been proven safe or effective. The significant price difference is a primary driver for consumer interest in these alternatives. Brand-name semaglutide injections can cost upwards of $1,300 per month without insurance, while compounded versions are often advertised for a few hundred dollars. Even the manufacturer of the brand-name drugs, Novo Nordisk, has introduced self-pay options that can lower the monthly cost to as little as $149 for new patients starting on the lowest doses. In response to the proliferation of compounded semaglutide, Novo Nordisk has filed over 130 lawsuits in 40 states against compounding pharmacies, telehealth companies, and medical spas. These legal actions allege patent infringement, false advertising, and unfair competition, with the company stating it does not supply its active pharmaceutical ingredient to compounding pharmacies. The FDA has also taken action, sending warning letters to companies for marketing their compounded products with claims of being equivalent to the FDA-approved brand-name drugs. The agency has reiterated that compounding should only occur when a commercially available drug is in shortage, a designation for semaglutide that was removed in February 2025. While some countries may see the introduction of true generic semaglutide sooner due to differing patent expiration dates—for instance, China's patent is expected to expire in 2026—the U.S. market will not have an FDA-approved generic until the current patents lapse. This has led to a complex and legally contentious market for weight-loss and diabetes medications.